Creo Medical Group PLC (GB:CREO)
LSE:CREO
Want to see GB:CREO full AI Analyst Report?
CREO Stock Chart & Stats
10.15 p
-0.13 p(-0.63%)
At close: 4:00 PM EST
10.15 p
-0.13 p(-0.63%)
Day’s Range― - ―
52-Week Range9.52 p - 18.50 p
Previous CloseN/A
Volume60.81K
Average Volume (3M)975.48K
Market Cap
£61.76M
Enterprise Value55.14M
Total Cash (Recent Filing)£12.40M
Total Debt (Recent Filing)£4.10M
Price to Earnings (P/E)10.7
Beta1.07
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding449,139,980
10 Day Avg. Volume668,834
30 Day Avg. Volume975,484
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.82
Price to Sales (P/S)6.81
P/FCF Ratio-2.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)£9.35M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityCreo’s relatively low debt and sizable equity base give the company financial flexibility typical of early-stage med-tech. This reduces near-term refinancing pressure, supports continued R&D and commercialization spending, and extends runway while the business scales toward sustainable operations.
Capital-plus-recurring Consumables ModelThe CROMA capital platform coupled with single-use instruments creates a durable revenue mix: one-time equipment sales drive site adoption while per-procedure consumables generate repeat revenues. This fosters customer stickiness and provides a path to higher margin, recurring cash flow as installed base grows.
Improving 2025 Revenue Momentum And Gross ProfitReported stronger revenue in 2025 with positive gross profit and reduced cash burn suggests improving unit economics. If sustained, this momentum could enable operating leverage as consumable volumes increase, lowering incremental costs and improving the path toward self-funding operations over the medium term.
Bears Say
Persistent Operating LossesCreo has recorded materially negative operating results throughout the period, indicating the core business is not yet profitable. Continued operating deficits limit free-cash generation, increase dependence on external funding, and delay the timing when internal cash flows can support growth investments.
Consistent Negative Cash FlowThe company’s history of negative operating and free cash flow signals persistent cash burn. This constrains strategic flexibility, raises refinancing or dilution risk, and means management must either materially improve margins or secure additional capital to sustain commercialization and R&D efforts.
Low Quality Reported Earnings / Negative ROEReturns on equity have been persistently negative and the 2025 net income uplift was driven by non-operating items rather than core operations. This undermines the durability of reported profitability and suggests shareholders have not yet seen reliable operational returns on invested capital.
Creo Medical News
CREO FAQ
What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 9.52 p and its highest was 18.50 p in the past 12 months.
What is Creo Medical Group PLC’s market cap?
Creo Medical Group PLC’s market cap is £61.76M.
When is Creo Medical Group PLC’s upcoming earnings report date?
Creo Medical Group PLC’s upcoming earnings report date is Sep 30, 2026 which is in 114 days.
How were Creo Medical Group PLC’s earnings last quarter?
Creo Medical Group PLC released its earnings results on May 22, 2026. The company reported -0.028 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.028 p.
Is Creo Medical Group PLC overvalued?
According to Wall Street analysts Creo Medical Group PLC’s price is currently Overvalued.
Does Creo Medical Group PLC pay dividends?
Creo Medical Group PLC does not currently pay dividends.
What is Creo Medical Group PLC’s EPS estimate?
Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Creo Medical Group PLC have?
Creo Medical Group PLC has 449,139,980 shares outstanding.
What happened to Creo Medical Group PLC’s price movement after its last earnings report?
Creo Medical Group PLC reported an EPS of -0.028 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.473%.
Which hedge fund is a major shareholder of Creo Medical Group PLC?
Currently, no hedge funds are holding shares in GB:CREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Creo Medical Stock Smart Score
Company Description
Creo Medical Group PLC
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Technical Analysis
Options Prices
Currently, No data available
---